Essential role of nuclear medicine technology in tositumomab and 131I-tositumomab therapeutic regimen for non-Hodgkin's lymphoma

Journal of Nuclear Medicine Technology

Volumn 34, Issue 2, 2006, Pages 67-73

  Cole, William C ^a   Barrickman, Jennifer ^b   Bloodworth, Glen ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

DIPHENHYDRAMINE; LUGOL; PARACETAMOL; POTASSIUM IODIDE; TOSITUMOMAB; TOSITUMOMAB I 131;

ARTICLE; DOSIMETRY; DRUG DISTRIBUTION; HUMAN; NONHODGKIN LYMPHOMA; NUCLEAR MEDICINE TECHNICIAN; RADIOIMMUNOTHERAPY; RECOMMENDED DRUG DOSE; WHOLE BODY SCINTISCANNING;

ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; LYMPHOMA, NON-HODGKIN; NUCLEAR MEDICINE; QUESTIONNAIRES; RADIOMETRY; WHOLE BODY IMAGING;

EID: 34250650538     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. American Cancer Society. Cancer Facts and Figures, 2005. Atlanta, GA: American Cancer Society; 2006.
2. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140-147.
3. 131I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2005;46(suppl 1):128S-140S.
4. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
5. 131I- tositumomab in non-Hodgkin's lymphoma [abstract]. J Nucl Med. 2000;41(suppl):79P.
6. 131I- tositumomab therapy. J Nucl Med. 2002;43:354-363.
7. GlaxoSmithKline. BEXXAR Site Training Manual. Research Triangle Park, NC: GlaxoSmithKline; 2005.